Philip R. Debruyne, MD, PhD, MSc, DABCP (CP), FRCP(Glasg), FCP is medical specialist in medical oncology and in clinical pharmacology & pharmaceutical medicine at the OECI-designated Kortrijk Cancer Centre of az groeninge (Kortrijk, Belgium; since 2008). His clinical specialty interests are: gynaecological & urological cancers and early phase clinical trials. Since 2016 he serves as an honorary visiting professor of Anglia Ruskin University (Biomedical and Health Innovation Research Centre (BHIRC), School of Allied Health & Social Care, Chelsmford, UK) and since 2021 as an honorary clinical professor of cancer pharmacology at the School of Nursing and Midwifery (Faculty of Health) of  the University of Plymouth, UK. His research interests include supportive cancer care and geriatric oncology.

He was born October 5th 1971 in Bruges. He received the degrees: Physician (Ghent University; 1996), standard ECFMG certificate + FSMB USMLE step 3 (MD equivalent; 1997 & 2004; USA), PhD in Medical Sciences (Ghent University; 2002) and MSc in Pharmacology (Human Investigation; Thomas Jefferson University, Philadelphia, USA; 2005). During and after completing an internship and residency training at Ghent University Hospital (1996-2002), he spent: 4 years (1997-2001) at the Laboratory of Experimental Cancer Research of the Department of Radiotherapy and Nuclear Medicine (Ghent University) as a research associate, 2 years (2002-2004) at the Division of Clinical Pharmacology of the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (Philadelphia, USA) as a post-doctoral fellow in Clinical Pharmacology and two years at the Department of General Medical Oncology of the Leuven University Hospitals as a clinical fellow in medical oncology. He obtained board certifications in Internal Medicine (Ghent University; 2004), Clinical Pharmacology (American Board of Clinical Pharmacology; 2005) and Medical Oncology (Leuven University; 2006). 

Prior to joining az groeninge Hospital in 2008, he held the positions of clinical senior lecturer in medical oncology (Clinical Trials; 2006-2008) in the Department of Cancer Sciences and Molecular Pathology of the University of Glasgow (UK) and the position of honorary consultant medical oncology at the Beatson West of Scotland Cancer Centre in Glasgow (2006-2008). From 2013 to 2016 he was an honorary senior fellow with the School of Health & Social Care of the University of Greenwich in London (UK)) were he led the Ageing & Cancer Research Cluster within the Centre for Positive Ageing.

Dr Debruyne was the recipient of a Sportvereniging tegen Kanker award (1998), the the two-year Merck Sharp & Dohme International Fellowship in Clinical Pharmacology Award (2002-2004), an Honorary Belgian American Educational Foundation (BAEF) Fellowship (2003), the 5th Pfizer Oncology Award 2020 and grants from: Bijzonder Onderzoeksfonds (BOF) Universiteit Gent, Vlaamse Kanker Liga, West Research Endowment Fund (UK), Pfizer (educational grant), Federale Overheidsdienst Volksgezondheid, Veiligheid van de VoedselKeten en Leefmilieu (Belgian Federal Government/National Cancer Plan), Kom Op Tegen Kanker (KOTK, Belgium), King Baudouin Foundation (KBF, Belgium) and Belgian Foundation against Cancer. He is a Fellow of the Royal College of Physicians & Surgeons of Glasgow qua Physician (FRCP), a Fellow of the American College of Clinical Pharmacology (FCP) and member of scientific societies and cooperative groups such as the European Organisation for Research and Treatment of Cancer (EORTC QoL group; EORTC GUCG representative in Older Adult Council), Cancer & Aging Research Group (CARG) and Belgian Society of Medical Oncology (BSMO; Supportive Care & Survivorship Task Forces). He was founding board member of the Kortrijk Oncology Fund charity within the King Baudouin Foundation (KBF). He previously served as associate editor of European Journal of Cancer Care and BMC Pharmacology and Toxicology and as guest editor for other journals. He serves, since 2021, as (substitute) board member (with experience in phase 1 trials) of the Clinical Trials College (Federal Public Service (FPS) Health, Food chain safety and Environment, Belgium). Since 2024 he serves as member of the credentials committee of the ACCP.